Novacyt (FR:ALNOV) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Novacyt S.A. reports a robust first half of 2024, with revenues of £10.3m and a significant increase in gross profit to £26.5m, thanks to a successful dispute settlement with the DHSC and strategic growth in their Reproductive Health and NIPT businesses. The company has also made substantial cost savings post-acquisition of Yourgene, maintaining a strong cash position at £32.9m while being debt-free, setting a strong foundation for future expansion and product development.
For further insights into FR:ALNOV stock, check out TipRanks’ Stock Analysis page.
